Apimeds Pharmaceuticals US Inc.

Apimeds US is publicly traded on the New York Stock Exchange (Ticker: APUS) and led by a team of experienced biopharma professionals committed to delivering meaningful healthcare advancements. We are actively pursuing licensing and acquisition opportunities to grow our pipeline and expand our impact.